1. Campo E, Jaffe ES, Cook JR, et al. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood 2022; 140: 1229-53.
2.
Vergier B, de Muret A, Beylot-Barry M, et al. Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases. French Study Group of Cutaneous Lymphomas. Blood 2000; 95: 2212-8.
3.
Olsen EA, Rook AH, Zic J, et al. Sézary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). J Am Acad Dermatol 2011; 64: 352-404.
4.
Ottevanger R, van Beugen S, Evers AWM, et al. Itch in patients with cutaneous T-cell lymphoma as a quality of life indicator. JAAD Int 2022; 9: 57-64.
5.
Szepietowski JC, Salomon J, Finlay AY, et al. Dermatology Life Quality Index (DLQI): Polish version. In: 11th International Congress of the European Society for Dermatology and Psychiatry. Giessen, Germany; May 5-7, 2005: 42.
6.
Bedyñska S, Brzezicka-Rotkiewicz A, eds. Statistical Signpost: A Practical Guide to Data Analysis in Social Sciences with Examples from Psychology. Warsaw, Academica 2007.
7.
Bedyñska S, Ksi¹¿ek M. A Practical Guide to the Use of Regression Models and Structural Equations. Warsaw, Academic Core 2012.
8.
Brzeziñski J. Methodology of Psychological Research. 3rd ed. Warsaw, PWN 2001.
9.
Field A. Discovering Statistics Using IBM SPSS Statistics. London, Sage 2009.
10.
Jonak C, Porkert S, Oerlemans S, et al. Health-related quality of life in cutaneous lymphomas: past, present and future. Acta Derm Venereol 2019; 99: 640-6.
11.
de Ruiter CC, Rustemeyer T. Biologics can significantly improve Dermatology Life Quality Index (DLQI) in psoriatic patients: a systematic review. Psoriasis (Auckl) 2022; 12: 99-112.
12.
Ali F, Vyas J, Finlay AY. Counting the burden: atopic dermatitis and health-related quality of life. Acta Derm Venereol 2020; 100: adv00161.
13.
Tsai YC, Hung CY, Tsai TF. Efficacy and safety of biologics and small molecules for moderate-to-severe hidradenitis suppurativa: a systematic review and network meta-analysis. Pharmaceutics 2023; 15: 1351.
14.
Ottevanger R, van Beugen S, Evers AWM, et al. Quality of life in patients with mycosis fungoides and Sézary syndrome: a systematic review of the literature. J Eur Acad Dermatol Venereol 2021; 35: 2377-87.
15.
Demierre MF, Gan S, Jones J, Miller DR. Significant impact of cutaneous T-cell lymphoma on patients’ quality of life: results of a 2005 National Cutaneous Lymphoma Foundation Survey. Cancer 2006; 107: 2504-11.
16.
Hristov AC, Tejasvi T, Wilcox RA. Mycosis fungoides and Sézary syndrome: 2019 update on diagnosis, risk-stratification, and management. Am J Hematol 2019; 94: 1027-41.
17.
Hodak E, Geskin L, Guenova E, et al. Real-life barriers to diagnosis of early mycosis fungoides: an International Expert Panel Discussion. Am J Clin Dermatol 2023; 24: 5-14.
18.
Chiba T, Nagai T, Osada SI, Manabe M. Diagnosis of mycosis fungoides following administration of dupilumab for misdiagnosed atopic dermatitis. Acta Derm Venereol 2019; 99: 818-9.
19.
Espinosa ML, Nguyen MT, Aguirre AS, et al. Progression of cutaneous T-cell lymphoma after dupilumab: case review of 7 patients. J Am Acad Dermatol 2020; 83: 197-9.
20.
Wilcox RA. Cutaneous T-cell lymphoma: 2017 update on diagnosis, risk stratification, and management. Am J Hematol 2017; 92: 1085-102.
21.
Arulogun SO, Prince HM, Ng J, et al. Long-term outcomes of patients with advanced-stage cutaneous T-cell lymphoma and large cell transformation. Blood 2008; 112: 3082-7.
22.
Soko³owska-Wojdy³o M, Olszewska B, Chmielowska E, et al. Primary cutaneous lymphomas. Diagnostic and therapeutic guidelines of the Polish Dermatological Society (PTD) and Polish Lymphoma Research Group (PLRG). Dermatol Rev 2023; 110: 647-74.
23.
Olsen EA, Whittaker S, Kim YH, et al. Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol 2011; 29: 2598-607.
24.
Scarisbrick JJ, Morris S. How big is your hand and should you use it to score skin in cutaneous T-cell lymphoma? Br J Dermatol 2013; 169: 260-5.
25.
Wohlmuth-Wieser I, Ramjist JM, Shear N, Alhusayen R. Morphologic features of cutaneous T-cell lymphomas using dermoscopy and high frequency ultrasound. J Clin Med 2020; 10: 17.
26.
Polañska A, Dañczak-Pazdrowska A, Olek-Hrab K, et al. High-frequency ultrasonography – new non-invasive method in assessment of skin lymphomas. Skin Res Technol 2018; 24: 517-21.
27.
Wang Y, Niu Z, Liu J, et al. Value of high-frequency ultrasound in accurate staging of mycosis fungoides/Sézary syndrome. J Ultrasound Med 2020; 39: 1927-37.
28.
Cisoñ H, Cisoñ W, Bia³ynicka-Birula B, et al. Mycosis fungoides unveiled following dupilumab treatment in a patient with a history of atopic dermatitis. Usefulness of HFUS in monitoring skin features. A review with a case report. Adv Dermatol Allergol 2024. doi:10.5114/ada.2024.143463.
29.
Engin B, Keçici AS, Uzun AÖ, et al. Psychiatric comorbidity, depression, and anxiety levels and quality of life of the patients with mycosis fungoides. Dermatol Ther 2020; 33: e13922.
30.
Terhorst-Molawi D, Lohse K, Ginter K, et al. Mast cells and tryptase are linked to itch and disease severity in mycosis fungoides: results of a pilot study. Front Immunol 2022; 13: 930979.
31.
Ayyalaraju RS, Finlay AY, Dykes PJ, et al. Hospitalization for severe skin disease improves quality of life in the United Kingdom and the United States: a comparative study. J Am Acad Dermatol 2003; 49: 249-54.
32.
Jennings T, Duffy R, Gochoco A, et al. Valchlor maintenance therapy for patients with mycosis fungoides who received low dose total skin electron beam treatment. Chin Clin Oncol 2019; 8: 13.
33.
Steinke S, Zeidler C, Riepe C, et al. Humanistic burden of chronic pruritus in patients with inflammatory dermatoses: results of the European Academy of Dermatology and Venereology Network on Assessment of Severity and Burden of Pruritus (PruNet) cross-sectional trial. J Am Acad Dermatol 2018; 79: 457-63.e5.
34.
Nawar T, Elsayad K, Müller EC, et al. Quality of life in patients with mycosis fungoides and Sézary syndrome undergoing low-dose total skin electron beam therapy with or without maintenance therapy. J Am Acad Dermatol 2022; 86: 889-91.
35.
Rencz F, Gulácsi L, Péntek M, et al. DLQI-R scoring improves the discriminatory power of the Dermatology Life Quality Index in patients with psoriasis, pemphigus and morphea. Br J Dermatol 2020; 182: 1167-75.
36.
Paudyal P, Apfelbacher C, Jones C, et al. “DLQI Seems to be ‘Action’, and Skindex-29 Seems to be ‘Emotion’”: qualitative study of the perceptions of patients with psoriasis or eczema on two common dermatology-specific quality of life measures. Acta Derm Venereol 2020; 100: adv00105.
37.
Graier T, Fink-Puches R, Porkert S, et al. Quality of life, anxiety, and depression in patients with early-stage mycosis fungoides and the effect of oral psoralen plus UV-A (PUVA) photochemotherapy on it. Front Med 2020; 7: 330.
38.
Vogiatzis R, Krüger W, Jünger M, Arnold A. Effects of extracorporeal photopheresis on quality of life and the course of diseases in patients with mycosis fungoides and graft-versus-host disease: a single-center analysis. Cureus 2023; 15: e38929.
